2 Names I’m Adding to as Expirations Create Dry Powder
Here are the top two positions worthy of additions as my cash position grows.
After Moderna’s Big News, Here Are Three Biotechs to Watch
I’m following these lesser-known names amid biopharma’s move on Wednesday.
Good Reports From Google, Texas Instruments Not Attracting Buyers
The news is hitting and there is some knee-jerk selling.
Keep an Eye Out for the Chance to Sell Biotech
XBI seems to be heading toward support and a bounce would be a good chance to do some selling.
Why I’m Eyeing Prices, Biotech and AI in Q3
As the second quarter skims some froth off the technology trade, let’s see why these three areas are key to watch in Q3.
Going Back to the Well in a Sector That’s Working
After years of underperformance, biotech is finally catching a nice bid. Here’s my strategy on a name showing promise.
This Biotech Could Become a ‘Sleeper’ Hit
Let’s look at this rising biopharma name working on several neurological condition treatments.
Warsh Is in No Rush to Cut Rates — And the Market Reacts
Hopes were high for some dovish comments but the new Fed Chair failed to deliver.
200+ Nasdaq Stocks Say This Market Isn’t So Great
Between new lows and an increase in downside volume it’s safe to say selling picked up quite a bit Wednesday.